Clinical Trials
12 trialsNCT07535840 2026-04-17
A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma
Tongji Hospital
Phase NA Not yet recruiting
NCT07396090 2026-02-09
Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase NA Not yet recruiting
NCT07243691 2025-11-24
Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma
Sir Run Run Shaw Hospital
Phase NA Recruiting
NCT07067450 2025-07-16
Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma
Sichuan University
Phase NA Not yet recruiting
NCT06607926 2024-09-23
Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC
Xuanwu Hospital, Beijing
Phase NA Not yet recruiting
NCT06363708 2024-04-12
Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial Cancer
Zhongnan Hospital
Phase NA Not yet recruiting
NCT06154967 2023-12-04
To Explore the Effect of Immune-induced Stereotactic Body Radiotherapy (SBRT) on Reversing Immunoresistance in Stage IIIc/IV Non-small Cell Lung Cancer (NSCLC)
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase NA Unknown
NCT06056115 2023-09-28
Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic
Hebei Medical University Fourth Hospital
Phase NA Recruiting
NCT05527808 2023-06-08
A Single-arm Exploratory Study of Neoadjuvant Therapy
Guangzhou Institute of Respiratory Disease
Phase NA Unknown
NCT05811793 2023-04-13
Efficacy and Safety of SCAI of Bevacizumab Combined With IC of Tislelizumab in the Treatment of Recurrent Glioblastoma.
Second Affiliated Hospital of Nanchang University
Phase NA Unknown
NCT05339581 2022-04-27
iPLENTY-pvtt
RenJi Hospital
Phase NA Unknown
NCT05277675 2022-03-14
RANT
Southwest Hospital, China
Phase NA Unknown